Severe anemia was observed in patients with CFH variants (38%), while C3 levels varied depending on complement abnormalities: indeed, half of the patients with C3 and MCP variants and 89% of the patients with anti-CFH antibodies showed decreased levels of C3. This evidence concerns the gene C3 and anemia.